Sage Therapeutics Insider Equity Cancelled in $8.50-per-Share Buyout
Rhea-AI Filing Summary
Form 4 highlights – Sage Therapeutics (SAGE): Director George Golumbeski reported the mandatory disposition of all remaining equity interests at the 31 Jul 2025 close of Sage’s merger with Supernus Pharmaceuticals.
- Common stock: 8,000 shares converted under Transaction Code “U” (merger) and cancelled for the right to receive $8.50 cash per share plus one contingent value right (CVR) of up to $3.50/share.
- In-the-money options: 13,593 options (strike $6.14) expiring 3 Jan 2035 and 21,500 options (strike $6.77) expiring 10 Jun 2035 were cancelled; each optionholder will receive cash equal to ($8.50 – strike) × shares plus the same CVR count.
- All equity with strike ≥ $8.50 received no consideration; none were reported.
- Post-merger ownership: 0 shares/options reported, indicating the director no longer holds SAGE securities.
The filing is procedural, confirming that Sage shareholders received immediate liquidity at closing and potential future milestone payments through the CVRs.
Positive
- Merger consideration confirmed: Shareholders receive $8.50 cash plus CVR worth up to $3.50 per share, providing immediate liquidity and potential upside.
- Deal consummation verified: Filing indicates effective merger close on 31 Jul 2025, eliminating execution risk for investors.
Negative
- None.
Insights
TL;DR – Cash-out confirms full merger completion and eliminates insider overhang.
The Form 4 shows Supernus closed its Sage takeover exactly as laid out in June’s Merger Agreement. Golumbeski’s 8 k shares and 35 093 in-the-money options were cancelled for $8.50 cash plus CVRs, wiping his direct stake to zero. This evidences that all minority holders received identical consideration, de-risking deal execution and removing potential insider selling pressure post-close. The added CVR upside keeps alignment for milestone achievements, while cash payment locks in immediate value. Overall, a routine but positive confirmation of transaction finality.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Stock Option (Right to Buy) | 13,593 | $0.00 | -- |
| Disposition | Stock Option (Right to Buy) | 21,500 | $0.00 | -- |
| U | Common Stock | 8,000 | $0.00 | -- |
Footnotes (1)
- This Form 4 reports securities disposed of pursuant to the terms of the Agreement and Plan of Merger (the "Merger Agreement"), dated as of June 13, 2025, among Sage Therapeutics, Inc. (the "Issuer"), Supernus Pharmaceuticals, Inc. ("Parent"), and Saphire, Inc., a wholly owned subsidiary of Parent ("Purchaser"), pursuant to which Purchaser completed a cash tender offer for shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer, effective as of July 31, 2025 (the effective time of the merger, the "Effective Time"). At the Effective Time, each issued and outstanding Share was cancelled and converted into the right to receive (i) $8.50 per Share in cash (the "Closing Amount"), plus (ii) one contingent value right ("CVR") per Share, each without interest and subject to the withholding of applicable taxes. (Continued from footnote 1) Each CVR represents the right to receive up to $3.50 per Share in cash upon the satisfaction of specified milestones, as described in the Form 8-K filed by the Issuer with the Securities and Exchange Commission on June 16, 2025. Pursuant to the Merger Agreement, at the Effective Time, each option to purchase Shares (a "Company Option") then outstanding and unexercised, whether or not vested, which had a per Share exercise price less than the Closing Amount was deemed fully vested and cancelled and converted into the right to receive (i) a cash payment (without interest and subject to the withholding of applicable taxes) equal to the product of (a) the excess of the Closing Amount over the per Share exercise price of such Company Option, multiplied by (b) the total number of Shares subject to such Company Option immediately prior to the Effective Time, plus (ii) one CVR for each Share subject to such Company Option immediately prior to the Effective Time. Each Company Option, whether or not vested, which had a per Share exercise price greater than or equal to the Closing Amount was cancelled with no consideration payable in respect thereof.
